home / stock / ipha / ipha short
Short Information | Innate Pharma S.A. (NYSE:IPHA)
Twenty Trading Day Totals | |
---|---|
Total Shorted Volume | 13,103 |
Total Actual Volume | 608,992 |
Short Trends | |
---|---|
Cover Days | 20 |
Short Days | 0 |
No Change Days | 0 |
Averages | |
---|---|
Average Short Volume | 655 |
Average Short Percentage | 3.71% |
Is there a IPHA Short Squeeze or Breakout about to happen?
See the IPHA Short Analysis for free Sign up or Login
Powered by Squeeze Report
Date | Open | Close | High | Low | Total Volume | Short Volume | Short Percentage |
---|---|---|---|---|---|---|---|
02-11-2020 | $7.5569 | $7.48 | $7.58 | $7.465 | 4,361 | 100 | 2.29% |
02-06-2020 | $7.4085 | $7.37 | $7.455 | $7.27 | 7,541 | 126 | 1.67% |
01-31-2020 | $7.08 | $7.02 | $7.08 | $6.71 | 12,435 | 239 | 1.92% |
01-30-2020 | $6.98 | $6.90 | $6.9979 | $6.88 | 4,216 | 50 | 1.19% |
01-29-2020 | $7.29 | $7.1321 | $7.29 | $7.1321 | 634 | 90 | 14.2% |
01-27-2020 | $7.26 | $7.01 | $7.2969 | $6.8201 | 6,759 | 200 | 2.96% |
01-24-2020 | $7.42 | $7.28 | $7.42 | $7.28 | 4,043 | 250 | 6.18% |
01-23-2020 | $7.5328 | $7.68 | $7.73 | $7.36 | 17,572 | 200 | 1.14% |
01-22-2020 | $7.71 | $7.60 | $7.71 | $7.50 | 14,246 | 5 | 0.04% |
01-21-2020 | $7.79 | $7.51 | $7.79 | $7.51 | 27,998 | 230 | 0.82% |
01-17-2020 | $7.62 | $7.605 | $7.6773 | $7.2501 | 15,658 | 1,360 | 8.69% |
01-16-2020 | $7.33 | $7.27 | $7.35 | $7.27 | 16,545 | 4 | 0.02% |
01-14-2020 | $6.98 | $7.00 | $7.03 | $6.96 | 5,606 | 727 | 12.97% |
01-13-2020 | $7.0596 | $6.86 | $7.0596 | $6.84 | 13,925 | 5 | 0.04% |
01-10-2020 | $6.95 | $6.95 | $6.995 | $6.84 | 78,624 | 1,000 | 1.27% |
01-09-2020 | $7.10 | $6.85 | $7.10 | $6.70 | 162,535 | 86 | 0.05% |
01-08-2020 | $7.50 | $7.61 | $7.61 | $7.46 | 29,732 | 3,214 | 10.81% |
01-07-2020 | $7.46 | $7.4598 | $7.49 | $7.36 | 13,706 | 160 | 1.17% |
01-06-2020 | $7.30 | $7.38 | $7.45 | $7.26 | 45,093 | 1,934 | 4.29% |
01-03-2020 | $7.36 | $7.17 | $7.46 | $7.17 | 127,763 | 3,123 | 2.44% |
News, Short Squeeze, Breakout and More Instantly...
Regulatory News: Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities ( Autorité des Marchés Financiers , or “ AMF ”) General Regulation, Innate Pharma SA (Euronext Pari...
SAR443579/IPH6101, ANKET ® platform lead asset, is a first-in-class NKp46/CD16-based NK cell engager targeting CD123 from a joint research collaboration between Innate Pharma and Sanofi, under development by Sanofi in R/R AML, B-ALL and HR-MDS SAR443579/IPH6101 continues ...
In heavily pretreated patients with mycosis fungoides, treatment with lacutamab results in meaningful anti-tumor activity regardless of baseline KIR3DL2 expression level. Lacutamab was well-tolerated with a safety profile consistent with prior studies. Innate will host a virtual KOL...